Reports Q4 revenue $62.3M vs. $74.7M last year. “Since taking on the role of CEO of Amarin (AMRN) last year, I have worked with our leadership ...

DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today announced financial results for the fourth quarter of 2024 and provided a review of fourth ...

Operator Welcome to Amarin Corporation's conference call to discuss its fourth-quarter and full-year 2024 business update and ...

Amarin is on course to significantly increase the number of patients eligible for treatment with its purified fish oil drug Vascepa after an FDA advisory committee voted in favour of an expanded ...

Generic drugmakers Hikma and Dr Reddy’s Laboratories have won a surprise victory in a US patent lawsuit that sets up early competition to cardiovascular drug Vascepa, Amarin’s only commercial ...

While Holt's departure has led to the appointment of Aaron Berg, Amarin's (AMRN) President of the U.S. Business, as his successor, Vascepa's commercial update concerns a major national pharmacy ...

Amarin Corp. Plc is a pharmaceutical company ... It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and ...

Amarin has a 52 week low of $0.43 and a 52 week ... and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for ...

Effective 1 April 2025, Austrian Reimbursement Marks 10th National Reimbursement for VAZKEPA® in Europe, Supporting Amarin’s Continued ... about the potential for VASCEPA (marketed as VAZKEPA ...